BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
BrainsWay announced the peer-reviewed publication of pilot study results evaluating its Deep TMS technology in 12 patients with co-occurring major depressive disorder and early-stage Alzheimer's disease, published in the Journal of Geriatric Psychiatry and Neurology. The study reported an 83.3% response rate and a 50% remission rate in depressive symptoms following 36 Deep TMS sessions using the H1 and H7 Coils, alongside QEEG changes suggesting reduced cortical slowing and improved brain connectivity.
Key figures
- Drug Name
- Deep TMS (H1 and H7 Coils)
- Phase Of Trial
- pilot study
- Tms sessions
- 36
- Response rate
- 83.3%
- Remission rate
- 50%
- Patients treated
- 12
- Delta band reduction
- 0-3 Hz in right temporal lobe
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.